Compounding evidence: management cites customer behavior, not just customer numbers, as proof the offering is winning
The model's full reasoning — Q2 2023 call → NOWe need to determine if management grounds its case in observed customer/counterparty behavior from the recent period, described concretely and currently, and treats it as core proof with more ahead. Let's review the transcript for management's explanations of why the business is working and will keep growing. Key points from Brian and Johnny: - Record revenue, system placements, installed base. - Focus on reagent pull-through, new panels, workflow improvements. - They mention "encouraging results" of emphasis on driving reagent growth, annualized pull-through increased to mid-$30,000 range. - They talk about field upgrades, software partners, etc. - They mention "growing momentum within our biopharma and CRO partners" but that's somewhat generic. - They mention "we continue to see robust growth in the translational markets with growing momentum within our biopharma and CRO partners as they leverage the PhenoImager HT platform" - that's a claim but not specific behavior. - They mention "our clinical market development and commercial team are leveraging the HT workflow improvements and best practices for advanced biopharma solutions, CLIA Lab or ABS to build a rapidly growing qualified CRO service provider network." - that's about their own efforts. - They mention "we are seeing encouraging results of our emphasis on driving reagent growth" - but that's their own results. - They mention "annualized second quarter reagent pull-through has now increased to the mid-$30,000 range" - that's a metric, not observed behavior. - They mention "as more PhenoCyclers paired with Fusion are up and running and as we see increasing utility of HT among biopharma and CROs" - "increasing utility" is vague. - They mention "we have partnered with leading software providers" - that's partnerships, not customer behavior. - They mention "we continue to make great progress in the downstream, translational, and clinical markets" - generic. - They mention "we continue to expand this ecosystem" - generic. In the Q&A, they answer questions about Fusion attach rate, pull-through, etc. They mention "our top 15 to 20 that are maybe fivefold above that mid-$30,000 range, they're all PCF customers." That's a specific observation about high-usage customers being PhenoCycler-Fusion users.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| AIRG | Airgain, Inc. | Q3 2023 | 2023-11-09 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| AWRE | Aware, Inc. | Q3 2022 | 2022-10-30 | F |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
ULCC · Q1 2023 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management points to concrete recent-period behavior: over half of GoWild Pass sales so far are from customers with no prior travel history with Frontier, plus overwhelmingly positive feedback and customers taking the product to social media. They treat this observed adoption pattern as central proof that the offering is working and will keep growing, with the 90%+ repeat rate and $85–$100 per-passenger contribution goals still ahead of current results. They also cite the shift in consumer demand patterns (leisure travel increasingly favoring peak days, expanding RASM premium from 19% to over 25%) as direct evidence of customer preference that is reshaping capacity and margins. These elements are presented as the behavioral foundation for continued growth rather than merely company results or plans.
PCRX · Q4 2017 → YESThe question is: Does management ground their case for why the business is working and will keep growing in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in concrete, observed counterparty behavior—specifically J&J’s sales team activating accounts and training customers on EXPAREL technique, with the number of activated accounts continuing to grow, plus J&J committing to a six-fold increase in PEAK programs (already exceeding 2018 plans). They also cite commercial payers paying for EXPAREL under C9290 as a medical benefit and hospitals gaining access through surgeon relationships, treating these patterns as central proof that the offering is being chosen and valued, with the business still early and expanding ahead.
PPC · Q1 2024 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in observed counterparty behavior by citing concrete patterns such as key customers increasing marketplace presence, deli and QSRs showing steady performance, brands growing faster than category averages in Europe, key customer partnerships driving growth in Mexico, and key customers outpacing industry growth in domestic chicken volumes and value-added products — all presented as recent, specific actions by buyers and partners that demonstrate genuine preference and commitment, with the business still building further through continued diversification and new opportunities.